CytomX Therapeutics reports Q2 EPS 0c, consensus (6c)

Reports Q2 revenue $18.7M, consensus $18.28M. Cash, cash equivalents and investments totaled $158.1M as of June 30, 2025, compared to $79.9M as of March 31, 2025. “Q2 2025 was an exciting quarter for CytomX as we announced positive initial clinical results for CX-2051 in advanced colorectal cancer, a very challenging disease to treat. Our data highlight CX-2051’s intentional design as a first-in-class, masked EpCAM-directed ADC with potential to improve upon the standard of care in late-line CRC. We are also delighted to have completed a financing with top-tier investors that enables CytomX to rapidly advance the CX-2051 development program. Looking ahead, we remain highly focused on our next anticipated CX-2051 clinical data update in Q1 2026 and to potentially launching a Phase 2 study in the first half of 2026,” said Sean McCarthy, D.Phil., CEO.